Skip to content

Nuzefatide Pevedotin

Bicycle Therapeutics' EphA2-targeting Bicycle Drug Conjugate — a bicyclic peptide carrying MMAE to a target that defeated every antibody approach before it. Since March 2026 it has been Bicycle's lead clinical asset, with FDA Orphan Drug Designation for pancreatic cancer and a 39-patient Phase 2 running in metastatic pancreatic ductal adenocarcinoma.

CPreliminaryLimited Data
Last updated 14 citations
TL;DR

Nuzefatide pevedotin is an experimental cancer drug: a tiny engineered peptide that finds a protein called EphA2 on tumour cells and delivers a cell-killing toxin to them. EphA2 has been a graveyard for cancer drugs — earlier antibody versions caused serious bleeding problems and were abandoned — and this one appears not to. It is early: the strongest results so far come from ten patients, and the current trial in pancreatic cancer has 39 places.

What is Nuzefatide Pevedotin?

Nuzefatide pevedotin is an investigational cancer therapy from Bicycle Therapeutics, developed for years under the code BT5528 and renamed when it received its International Nonproprietary Name in early 2026. Both names are in active use across the registry, the literature and news coverage. It is worth settling a persistent confusion at the outset. Bicycle has two clinical conjugates with similar names and they are routinely mixed up in secondary coverage. Nuzefatide pevedotin, formerly BT5528, targets EphA2 and is now in a Phase 2 trial in pancreatic cancer. Zelenectide pevedotin, formerly BT8009, targets Nectin-4 and was studied in the Duravelo trials in bladder, breast and lung cancer. The shared 'pevedotin' stem is not evidence of kinship beyond the payload: it designates the monomethyl auristatin E cytotoxin and linker that both molecules carry. Target and indication are the reliable way to tell a report about one from a report about the other. The molecule is a bicyclic peptide — a short synthetic peptide constrained into two loops by a central chemical scaffold, giving a sub-two-kilodalton molecule the shape-specific, high-affinity binding normally requiring an antibody — joined through a cleavable linker to MMAE, a microtubule-disrupting cytotoxin. The target is what makes this programme interesting. EphA2 is a receptor tyrosine kinase overexpressed across many solid tumours, strongly associated with poor prognosis, and particularly prominent in cancers with few good options, including pancreatic and head and neck. It has also been one of oncology's more conspicuous failures. MEDI-547, an EphA2-targeting antibody-drug conjugate, entered Phase 1 and was halted over bleeding and coagulation events. DS-8895a, MM-310 and dasatinib all stalled for efficacy or safety reasons. By the late 2010s EphA2 was a target most of the field had written off. Bicycle's argument is that the problem was never the target but the format — that an antibody's long circulation and slow tissue penetration concentrated toxicity in the vasculature rather than the tumour, and that a small peptide with a plasma half-life under an hour would not. The first-in-human study, published in the Journal of Clinical Oncology in 2024, supported the safety half of that argument: no bleeding signal emerged, and the toxicity profile looked like an ordinary MMAE conjugate rather than like MEDI-547. The efficacy half remains open. At the recommended Phase 2 dose in that study the objective response rate was 6.7%. The much better numbers that have followed — a 40% confirmed response rate in combination with nivolumab — come from ten EphA2-positive patients at a conference, not from a published trial. Since Bicycle's March 2026 reprioritisation, nuzefatide pevedotin has been the company's lead clinical asset. It received FDA Orphan Drug Designation for pancreatic cancer in September 2026.

What Nuzefatide Pevedotin Is Investigated For

Nuzefatide pevedotin has a strong story about a target and a thin story about results, and the two should not be conflated. The target story is genuinely substantial. EphA2 had defeated every serious attempt to drug it: MEDI-547 was halted in Phase 1 over bleeding and coagulation events, and DS-8895a, MM-310 and dasatinib all failed to establish themselves. The published first-in-human study of nuzefatide pevedotin in 45 patients found no haemorrhage signal and a toxicity profile indistinguishable in kind from any other MMAE conjugate — nausea, diarrhoea, fatigue and neutropenia. That is a real contribution: it suggests EphA2's reputation was a property of antibody pharmacokinetics rather than of the biology. The efficacy story is much earlier than the headline figures suggest. In the published dose escalation, the objective response rate at the recommended Phase 2 dose of 6.5 mg/m2 every two weeks was 6.7%, with a disease control rate of 20%. The widely quoted 40% confirmed response rate comes from AACR 2026 and describes four responses among ten EphA2-positive patients receiving nuzefatide pevedotin with nivolumab after progression on a checkpoint inhibitor; the 100% figure describes three of three patients in that cohort who had not previously received an MMAE-based drug. Those are company-reported, unpublished, biomarker-selected numbers in single-digit patient counts. They are a reason to run the next trial, not a result. Pancreatic cancer is where the programme now sits, and the choice is defensible on preclinical grounds — EphA2 was expressed in all 16 pancreatic patient-derived xenograft models Bicycle tested, with 10 of 14 sensitive to the drug — and on strategic grounds, since it is an orphan indication with almost no competition and now carries Orphan Drug Designation. But the registered trial is 39 patients, single-arm, with objective response rate as its primary endpoint, in a disease where single-agent response rates are usually close to zero. That is a signal-finding study. It is not a registration path, and it should not be read as one.

Metastatic pancreatic ductal adenocarcinoma, second line and beyond
Preliminary30%
Metastatic urothelial cancer after checkpoint inhibitor, with nivolumab
Preliminary30%
Making EphA2 druggable after a decade of antibody failures
Emerging50%
Activity in patients who have already progressed on an MMAE-based antibody-drug conjugate
Limited15%
Head and neck squamous cell carcinoma
Limited15%

History & Discovery

The EphA2 story begins with a decade of failure. The receptor had everything a targeted-therapy programme wants — high expression across solid tumours, low expression in normal adult tissue, a documented contribution to oncogenesis, angiogenesis and metastasis, and biopsy expression that predicted poor patient outcomes. Drug discovery groups pursued it with small molecules, peptides and nanoparticles, but only antibody-drug conjugates reached the clinic. MEDI-547 showed encouraging preclinical antitumour activity and progressed to Phase 1, where it was halted over bleeding and coagulation events. DS-8895a, MM-310 and dasatinib each stalled in turn. By the late 2010s EphA2 was a target with a reputation. Bicycle Therapeutics, built on the bicyclic peptide chemistry developed in Sir Greg Winter's laboratory at the MRC Laboratory of Molecular Biology in Cambridge, approached it with a specific hypothesis about format. The 2020 Molecular Cancer Therapeutics paper describing BT5528 is unusually explicit about this: it sets out to compare and contrast the pharmacokinetics of antibody-based and Bicycle-based targeting, and to argue that the efficacy-toxicity trade-off is driven by delivery characteristics rather than by the target. If EphA2 is expressed on tumour endothelium as well as tumour cells, an agent that circulates for days concentrates its payload in the vascular compartment — which is what bleeding toxicity looks like. An agent cleared renally within the hour does not. The first-in-human study (NCT04180371) opened in November 2019. In December 2021, Cancer Discovery reported that a tumour-penetrating bicyclic peptide had yielded clinical responses in three patients with ovarian and urothelial cancers without any of the toxicity issues that had plagued other EphA2-directed candidates — an early, small, but directionally important signal. The full dose-escalation results were published in the Journal of Clinical Oncology in October 2024, establishing the recommended Phase 2 dose of 6.5 mg/m2 every two weeks and reporting a 6.7% response rate at that dose. The safety hypothesis had held; the efficacy question was wide open. March 2026 changed the programme's position entirely, through no action of its own. Bicycle announced a strategic reprioritisation 'to focus on BT5528 and next generation Bicycle conjugates', cut approximately 30% of its workforce, discontinued the breast and lung trials of its Nectin-4 conjugate and deprioritised that programme after concluding its registrational trial design was no longer an acceptable approval path. BT5528 — which received its International Nonproprietary Name, nuzefatide pevedotin, in the same announcement — became the lead clinical asset by default as much as by merit. The Phase 2 pancreatic trial began enrolling that month, with the first patient dosed in April 2026. AACR data followed on 20 April 2026, and FDA Orphan Drug Designation for pancreatic cancer in September 2026. The programme is therefore carrying more weight than its data alone would justify, which is worth remembering when reading company communications about it. Bicycle has $469.9 million in cash as of 30 September 2026 and a runway into 2030, so there is time for the Phase 2 to report. But the asset that now leads the pipeline has one published trial, a 6.7% response rate at its recommended dose in that trial, and a set of much better numbers from ten patients at a conference.

How It Works

Many solid tumours cover themselves in a protein called EphA2, and tumours that do tend to behave badly. Nuzefatide pevedotin is a very small engineered peptide that latches onto EphA2 while carrying a potent cell-killing toxin on a chemical tether designed to snap inside tumour tissue. Because the peptide is a fraction of an antibody's size, it floods out of the bloodstream into the tumour within minutes and is flushed out through the kidneys within the hour — which appears to be why it does not cause the bleeding problems that killed earlier EphA2 drugs.

EphA2 is a receptor tyrosine kinase in the erythropoietin-producing hepatocellular receptor family. It is expressed at high levels in many solid tumours and at low levels in normal adult tissue, and high expression in biopsies predicts poor outcome — the textbook profile of a good antibody-drug conjugate target. It also contributes directly to oncogenesis, tumour-associated angiogenesis and metastasis, so it is not merely a surface marker. Nuzefatide pevedotin consists of an EphA2-targeting bicyclic peptide conjugated to monomethyl auristatin E through a cleavable linker. The 2020 preclinical paper describes conjugation to maleimidocaproyl-monomethyl auristatin E; the 2026 review describes the construct as using a valine-citrulline cleavable linker, the standard protease-labile dipeptide that is stable in plasma and cleaved by cathepsin B and related enzymes in the tumour environment. The bicyclic architecture — a short synthetic peptide constrained into two loops around a central scaffold — is what gives a molecule of under two kilodaltons the defined three-dimensional conformation needed for high-affinity, selective binding. MMAE itself blocks microtubule polymerisation, arresting dividing cells in mitosis, and is cell-permeant once released, so it can kill neighbouring tumour cells that do not express the target. The pharmacokinetics are the whole thesis of the molecule, and the clinical values are unusually extreme. In patients, nuzefatide pevedotin has a half-life of 0.4 to 0.7 hours, while released MMAE has a half-life of 35 to 47 hours. The conjugate is therefore present in circulation for well under a working day while the toxin it delivers persists in tissue for days. Bicycle's preclinical characterisation described this as rapid uptake into tumours and fast renal elimination, followed by persistent toxin levels in the tumour without prolonged exposure of the vasculature to the parent drug — and reported that this produced more favourable toxicology findings in rats and monkeys than were observed with MEDI-547 in preclinical and clinical studies. That comparison is the mechanistic argument for why this programme survived where the antibodies did not. EphA2 is expressed on tumour endothelium as well as on tumour cells, and an antibody-drug conjugate that circulates for days delivers most of its payload to the vascular compartment. MEDI-547's dose-limiting bleeding and coagulation events are consistent with that. A conjugate cleared renally within an hour spends comparatively little time in contact with the endothelium while still achieving tumour exposure through rapid diffusion. The clinical record to date is consistent with the prediction: no haemorrhage-related events have been reported in the dose-escalation study or in the nivolumab combination, and the observed toxicities — nausea, diarrhoea, fatigue, neutropenia — are the generic signature of an MMAE conjugate rather than anything EphA2-specific. The same pharmacokinetics impose a cost. A parent molecule that clears in under an hour cannot be dosed every three weeks the way an antibody can; the clinical schedules have been weekly or every two weeks, and the therapeutic effect depends on repeated short pulses of exposure rather than sustained circulation. Whether that pulsatile delivery is sufficient against a dense, poorly perfused tumour like pancreatic adenocarcinoma is precisely what the Phase 2 trial is testing.

Evidence Snapshot

Overall Confidence42%

Human Clinical Evidence

One published Phase 1 dose escalation, one unpublished combination dataset reported at a conference, and one recruiting Phase 2. The first-in-human study (NCT04180371), published in the Journal of Clinical Oncology in October 2024, enrolled 45 patients across doses from 2.2 mg/m2 once weekly to 10.0 mg/m2 once every two weeks, using a 3+3 design for the first two levels and then a Bayesian logistic regression model. The most frequent drug-related adverse events were nausea (44.4%), diarrhoea (35.6%) and fatigue (33.3%), and the most common grade 3 or higher drug-related event was neutropenia or decreased neutrophil count (22.2%). The recommended Phase 2 dose was 6.5 mg/m2 every two weeks, and at that dose the overall response rate was 6.7% with a disease control rate of 20.0%. Pharmacokinetics were generally dose-proportional, with a parent half-life of 0.4 to 0.7 hours and an MMAE half-life of 35 to 47 hours. At AACR in April 2026 Bicycle reported combination data: 14 patients with metastatic urothelial cancer who had progressed on a checkpoint inhibitor, ten of whom had received enfortumab vedotin, treated at 6.5 mg/m2 every two weeks with nivolumab 480 mg every four weeks, data cutoff 9 February 2026. Confirmed response rate was 40% (4 of 10) in EphA2-positive tumours and 100% (3 of 3) in EphA2-positive patients who were MMAE-naive, with responders and patients achieving at least 16 weeks of stable disease having remained on treatment for a minimum of 56 weeks. One dose-limiting toxicity was reported — grade 3 fatigue lasting five days — and no grade 3 or higher drug-related adverse events of clinical interest and no haemorrhage events occurred. The Phase 2 pancreatic trial (NCT07450859) opened on 5 March 2026 with 39 estimated participants, monotherapy at 8 mg/m2 every two weeks, objective response rate as primary endpoint, and estimated primary completion in March 2029.

Animal / Preclinical

The 2020 Molecular Cancer Therapeutics paper is the foundational preclinical work and is explicitly framed as a comparison with the failed antibody approach. It reports rapid uptake into tumours and fast renal elimination followed by persistent toxin levels in tumour without prolonged exposure of the parent drug in the vasculature, and states that this profile gave more favourable toxicology findings in rats and monkeys than were observed with MEDI-547. The pancreatic work reported at AACR 2026 is the basis for the current indication: EphA2 expression was found in all 16 pancreatic ductal adenocarcinoma patient-derived xenograft models tested, with 10 of 14 models sensitive to nuzefatide pevedotin and six of those highly sensitive, alongside reported activity in EphA2-expressing head and neck squamous cell carcinoma models. Xenograft sensitivity has a poor record of predicting clinical benefit in pancreatic cancer specifically, where the stromal barrier that limits drug delivery is not well reproduced in these models.

Mechanistic Rationale

Strong on target validation and on the specific hypothesis this molecule tests. EphA2's association with poor prognosis across solid tumours is long-established, and the argument that antibody pharmacokinetics rather than the target itself caused the historical failures is coherent, mechanistically specific and now supported by clinical safety data — no bleeding signal has emerged across the programme. The weaker link is the step from a tolerable drug to an effective one. A 6.7% response rate at the recommended Phase 2 dose in the published study is not what target validation looks like, and the reasons offered for the gap — a higher monotherapy dose, biomarker selection for EphA2 expression, and combination with checkpoint blockade — are all plausible and all untested at scale. The pancreatic indication adds a delivery problem the mechanism does not address: a drug that relies on rapid diffusion from circulation faces a tumour defined by dense desmoplastic stroma and poor perfusion.

Research Gaps & Open Questions

What the current literature has not yet settled about Nuzefatide Pevedotin:

  • 01Whether the 6.7% response rate at the recommended Phase 2 dose in the published study or the 40% rate in ten selected patients at AACR is closer to the drug's real activity. Nothing in the public record reconciles them.
  • 02Whether EphA2 expression testing actually enriches for response. The AACR figures were reported in EphA2-positive subsets with no stated comparison to EphA2-negative patients, so the biomarker hypothesis is assumed rather than demonstrated.
  • 03Whether a drug that depends on rapid diffusion from circulation can reach tumour cells in pancreatic ductal adenocarcinoma, a cancer defined by dense desmoplastic stroma and poor perfusion. The xenograft models that support the indication do not reproduce that barrier well.
  • 04Whether the apparent activity in patients who had already progressed on enfortumab vedotin reflects genuine non-cross-resistance to a different target carrying the same payload, or the small numbers involved.
  • 05Long-term safety in the more than 150 patients Bicycle says have received the drug. Only the 45-patient dose escalation has been published.
  • 06Whether the absence of bleeding and coagulation toxicity holds at larger scale, and whether anticoagulation or antiplatelet therapy modifies it. This is the specific failure mode that ended the earlier EphA2 programmes.
  • 07What the 8 mg/m2 monotherapy dose does that 6.5 mg/m2 did not, which the Phase 2 will be the first study to show.
  • 08Dosing in renal impairment, given renal elimination and no dedicated study.
  • 09Whether a 39-patient single-arm Phase 2 can generate a signal strong enough to justify a randomised trial in a disease where single-agent response rates are usually near zero.

Forms & Administration

Nuzefatide pevedotin is given by intravenous infusion in an oncology clinic, dosed by body surface area in mg/m2. There is no other route and no compounded or research-chemical form of any kind. The dose-escalation study explored 2.2 mg/m2 once weekly through 10.0 mg/m2 once every two weeks, and selected 6.5 mg/m2 every two weeks as the recommended Phase 2 dose. That is the dose used in the nivolumab combination cohort, given with nivolumab 480 mg every four weeks. For monotherapy, Bicycle reported at AACR 2026 that 8 mg/m2 every two weeks is the preferred dose and that it was selected for the pancreatic Phase 2 trial. The every-two-week schedule reflects the molecule's pharmacokinetics rather than convenience. With a parent half-life under an hour, dosing cannot be stretched the way it can for an antibody-drug conjugate; what carries the effect between doses is the released MMAE retained in tumour tissue, which has a half-life of 35 to 47 hours.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Typical Range

6.5 mg/m2 intravenously (combination); 8 mg/m2 (preferred monotherapy dose)

Frequency

Once every two weeks

Timing Considerations

No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.

Protocol Notes

These are investigational trial doses for an intravenous cytotoxic conjugate, recorded so the published results can be interpreted. There is no prescribable dose and no administration outside an oncology trial. The dose-escalation study explored 2.2 mg/m2 once weekly through 10.0 mg/m2 once every two weeks, using a 3+3 design for the first two dose levels and a Bayesian logistic regression model thereafter, and selected 6.5 mg/m2 every two weeks as the recommended Phase 2 dose. That dose was carried into the nivolumab combination cohort, given alongside nivolumab 480 mg every four weeks. For monotherapy, Bicycle reported at AACR 2026 that 8 mg/m2 every two weeks is the preferred dose and that it was selected for the pancreatic Phase 2 trial. The dose increase is worth noting when comparing results across the programme. The 6.7% response rate from the published study was measured at 6.5 mg/m2, which is below the dose the company now considers optimal for single-agent use — one of several reasons the published efficacy figure may understate what the current regimen can do, and one of the things the Phase 2 trial will establish.

Nuzefatide pevedotin is an investigational intravenous cytotoxic agent with no marketing approval in any country. It is administered only in clinical trials under oncology supervision with haematological monitoring.

Timeline of Effects

Onset

The conjugate distributes out of the circulation into tissue within minutes and is cleared with a half-life of 0.4 to 0.7 hours in patients; what persists is released MMAE, with a half-life of 35 to 47 hours. Clinically, response is assessed radiographically on the trial schedule, and no earlier biomarker of activity has been reported for this compound.

Peak Effect

The most informative durability figure in the public record comes from the nivolumab combination cohort reported at AACR 2026: patients with a partial response or at least 16 weeks of stable disease had been on treatment for a minimum of 56 weeks, with most still on treatment at the February 2026 data cutoff. A year or more of continuous treatment without discontinuation is a meaningful observation in heavily pretreated metastatic urothelial cancer, though it describes a small number of patients selected by having already responded.

After Discontinuation

Not characterised for this compound. The conjugate itself leaves the circulation within an hour, so there is no pharmacological tail from the parent drug; released MMAE clears over a few days. The residual effect that matters for any auristatin conjugate is cumulative peripheral neuropathy, which can persist after the last dose before improving — no compound-specific resolution data have been published.

Common Questions

Is nuzefatide pevedotin the same as zelenectide pevedotin?

No, and this is the single most frequent error in coverage of Bicycle Therapeutics. Nuzefatide pevedotin, formerly BT5528, targets EphA2 and is in Phase 2 for metastatic pancreatic ductal adenocarcinoma. Zelenectide pevedotin, formerly BT8009, targets Nectin-4 and ran the Duravelo trials in bladder, breast and lung cancer before being deprioritised in March 2026. They share the 'pevedotin' stem because they carry the same monomethyl auristatin E payload and linker, not because they share a targeting element. To identify which drug a report concerns, check the target or the trial name: EphA2 and pancreatic cancer mean nuzefatide; Nectin-4 and Duravelo mean zelenectide.

Why did earlier EphA2 drugs fail?

MEDI-547, an EphA2-targeting antibody-drug conjugate, reached Phase 1 and was halted over bleeding and coagulation events — a toxicity that effectively ended enthusiasm for the target. DS-8895a, MM-310 and dasatinib all stalled for efficacy or safety reasons. The hypothesis behind nuzefatide pevedotin is that the problem was format rather than target: an antibody circulates for days to weeks and penetrates tissue slowly, so the toxin spends most of its time in the vasculature, where EphA2 is expressed on endothelium. A bicyclic peptide with a plasma half-life of 0.4 to 0.7 hours in patients does not. Bicycle's preclinical work reported more favourable toxicology in rats and monkeys than was seen with MEDI-547, and no haemorrhage events have been reported in the clinical programme to date.

What do the 40% and 100% response rates actually mean?

They come from AACR 2026 and describe a very small, selected group. Fourteen patients with metastatic urothelial cancer who had progressed on a checkpoint inhibitor — ten of whom had also received enfortumab vedotin — were given nuzefatide pevedotin at 6.5 mg/m2 every two weeks with nivolumab 480 mg every four weeks. Among patients with EphA2-positive tumours, four of ten had a confirmed response (40%); among the three EphA2-positive patients who had not previously received an MMAE-based drug, three of three responded (100%). A denominator of three cannot support a percentage in any meaningful sense. The durability was the genuinely interesting part: patients with a partial response or at least 16 weeks of stable disease had been on treatment for a minimum of 56 weeks. These figures are company-reported and have not been peer-reviewed.

Why pancreatic cancer?

Three reasons, in descending order of scientific weight. EphA2 is highly expressed in pancreatic ductal adenocarcinoma and associated with poor prognosis, and Bicycle reported EphA2 expression in all 16 pancreatic patient-derived xenograft models it tested, with 10 of 14 models sensitive to nuzefatide pevedotin and six of those highly sensitive. The company also has a gallium-68-labelled EphA2 imaging agent that has produced PET/CT data in pancreatic patients, giving it a way to confirm target expression in the tumours it is treating. And pancreatic cancer is an orphan indication with very few effective second-line options, which both lowers the competitive bar and earned the programme FDA Orphan Drug Designation in September 2026. The weakness is the same one that applies to every pancreatic programme: response rates for single agents in this disease are usually near zero, which is why a 39-patient single-arm trial is appropriate for finding a signal and inadequate for proving one.

Can a patient enrol in a trial?

Yes. The Phase 2 study in metastatic pancreatic ductal adenocarcinoma (NCT07450859, BT5528-201) began on 5 March 2026 and is recruiting, with an estimated 39 participants receiving nuzefatide pevedotin as monotherapy and objective response rate as the primary endpoint. The original Phase 1/2 study (NCT04180371) is active but no longer recruiting. Bicycle has also registered a continued-access protocol (NCT07681674) for participants already receiving a Bicycle investigational product, which is a mechanism for keeping existing patients on drug rather than a route for new ones. The drug is not approved anywhere and is not available outside a trial.

What dose is being used now?

The dose has moved up. The published first-in-human study selected 6.5 mg/m2 every two weeks as the recommended Phase 2 dose, and that is the dose used in the nivolumab combination cohort. For monotherapy, Bicycle reported at AACR 2026 that 8 mg/m2 every two weeks is the preferred dose and that it was selected for the pancreatic Phase 2. The difference matters when reading older results: the 6.7% response rate from the dose-escalation study was measured at 6.5 mg/m2, below the dose the company now uses as monotherapy.

What regulatory designations does it hold?

Two, both from the FDA and neither an approval. Fast Track designation for the treatment of adults with previously treated locally advanced or metastatic urothelial cancer, confirmed in Bicycle's FY2025 annual report. And Orphan Drug Designation for pancreatic cancer, granted in September 2026, which brings tax credits, user-fee exemptions and up to seven years of market exclusivity if the drug is eventually approved. Orphan designation is granted on the basis that a condition affects fewer than 200,000 people in the United States with a plausible scientific rationale; it is not an efficacy judgement, and a large proportion of orphan-designated drugs never reach the market.

Who Nuzefatide Pevedotin Is NOT For

Contraindications
  • •Anyone without an EphA2-expressing malignancy — this is targeted cytotoxic chemotherapy with no application outside oncology
  • •Pregnancy and breastfeeding; MMAE is a microtubule inhibitor and is expected to be embryotoxic
  • •Significant baseline neutropenia or haematological compromise, given a 22.2% rate of grade 3 or higher neutropenia in the dose-escalation study
  • •Pre-existing moderate or severe peripheral neuropathy, where any MMAE-based agent would be expected to worsen it
  • •No paediatric data exist; all trials have enrolled adults only
  • •Renal impairment has not been studied in a dedicated trial, which is a notable gap for a conjugate that is renally eliminated

Drug & Supplement Interactions

The only combinations studied are with checkpoint inhibitors. The original Phase 1/2 trial included a dose-escalation arm combining BT5528 with nivolumab, and the AACR 2026 dataset describes 6.5 mg/m2 every two weeks with nivolumab 480 mg every four weeks in 14 patients — a combination that was reported as generally well tolerated, with one dose-limiting toxicity of grade 3 fatigue and no grade 3 or higher drug-related adverse events of clinical interest. That is a small dataset, but it is the only formal combination experience in the public record. No dedicated drug-interaction study has been published, so the remaining expectations come from the payload rather than the peptide. Released MMAE is a substrate for CYP3A4 and P-glycoprotein, so strong CYP3A4 inhibitors and inducers and P-gp modulators would be expected to alter free MMAE exposure — the standard caution across every auristatin conjugate, extrapolated here rather than measured. Agents that independently cause peripheral neuropathy, including taxanes, platinum compounds and vinca alkaloids, would be expected to compound MMAE's neurological class effect, and myelosuppressive chemotherapy would compound the neutropenia. One interaction question is specific to this molecule's history and remains open. EphA2 is expressed on tumour vasculature, and the toxicity that ended the MEDI-547 programme was haemorrhagic. No bleeding events have been reported with nuzefatide pevedotin, but whether concurrent anticoagulation or antiplatelet therapy changes that picture has not been examined in any published analysis, and the clinical dataset is small enough that a low-frequency interaction would not yet be visible.

Safety Profile

Safety Information

Common Side Effects

Nausea — 44.4% of patients in the published dose-escalation studyDiarrhoea — 35.6%Fatigue — 33.3%; the single dose-limiting toxicity reported in the nivolumab combination was grade 3 fatigue lasting five days, which improved to grade 1 without dose reductionNeutropenia or decreased neutrophil count — the most common grade 3 or higher drug-related adverse event, at 22.2%Peripheral neuropathy — an expected class effect of MMAE-based agents, though not among the most frequently reported events in the dose-escalation publication

Cautions

  • • This is an intravenous cytotoxic conjugate given in an oncology setting; the payload is a microtubule inhibitor that would be lethal unconjugated at these doses
  • • Grade 3 or higher neutropenia in 22.2% of dose-escalation patients requires blood count monitoring
  • • No bleeding or coagulation signal has been reported, which is the specific concern that ended the MEDI-547 programme — but the clinical dataset is small enough that a low-frequency vascular toxicity could still be undetected
  • • Published clinical safety data cover 45 patients in dose escalation; Bicycle has stated that more than 150 patients have received nuzefatide pevedotin in total, but that larger dataset has not been published
  • • The nivolumab combination safety data describe 14 patients and have not been peer-reviewed

What We Don't Know

The efficacy question dominates everything else: a 6.7% response rate at the recommended Phase 2 dose in the published study and a 40% rate in ten selected patients at a conference are not reconcilable from the public record, and only a properly sized trial will resolve which is closer to the truth. Beyond that, long-term tolerability is uncharacterised, though the report that responding patients had remained on treatment for at least 56 weeks is encouraging for cumulative neuropathy. Whether EphA2 expression testing actually enriches for response is assumed rather than demonstrated — the AACR figures were reported in EphA2-positive subsets without a stated comparison to EphA2-negative patients. Activity in pancreatic cancer rests entirely on xenograft models and will not be known until the Phase 2 reports, with estimated primary completion in March 2029.

Myths & Misconceptions

Myth

Nuzefatide pevedotin and zelenectide pevedotin are the same drug under two names.

Reality

They are two different molecules from the same company with two different targets. Nuzefatide pevedotin, formerly BT5528, binds EphA2 and is in Phase 2 for pancreatic cancer. Zelenectide pevedotin, formerly BT8009, binds Nectin-4 and ran the Duravelo trials in bladder, breast and lung cancer before being deprioritised in March 2026. They share the 'pevedotin' stem because they carry the same MMAE payload and linker. Multiple news outlets have attributed one drug's trial results to the other; checking the target or the trial name settles it immediately.

Myth

It achieved a 40% response rate in urothelial cancer.

Reality

Four patients out of ten responded, in an EphA2-positive subgroup of a 14-patient cohort treated in combination with nivolumab, reported at a conference and not peer-reviewed. The companion figure of 100% describes three patients out of three. The published response rate for this drug, in 45 patients at its recommended Phase 2 dose, was 6.7%. Both sets of numbers are real; only one has been through peer review, and it is the lower one.

Myth

Orphan Drug Designation for pancreatic cancer means the FDA sees promise in the data.

Reality

It does not. Orphan designation is granted on the basis that a drug targets a condition affecting fewer than 200,000 people in the United States with a plausible scientific rationale — an administrative threshold, not an efficacy assessment. It confers tax credits, user-fee exemptions and up to seven years of market exclusivity if the drug is eventually approved. Many orphan-designated drugs never reach the market, and the designation says nothing about the 39-patient trial that will determine this one's future.

Myth

Bicycle made nuzefatide pevedotin its lead asset because the data were compelling.

Reality

The elevation was as much a consequence of what happened to the other programme. In March 2026 Bicycle deprioritised zelenectide pevedotin — not for efficacy or safety reasons but because the standard of care in urothelial cancer had moved and its registrational trial design was no longer an acceptable approval path — cut roughly 30% of its workforce, and announced a reprioritisation 'to focus on BT5528 and next generation Bicycle conjugates.' Nuzefatide pevedotin's own data did not change that month. Its position in the pipeline did.

Myth

EphA2 failed as a target, so this will too.

Reality

This is the claim the programme has actually tested, and so far it has come out the other way. MEDI-547's dose-limiting bleeding and coagulation events were consistent with an antibody delivering MMAE to a target expressed on tumour endothelium over days of circulation. A bicyclic peptide with a plasma half-life of 0.4 to 0.7 hours spends comparatively little time in that compartment, and across the clinical programme to date no haemorrhage-related events have been reported, with a toxicity profile that looks like a generic MMAE conjugate rather than anything EphA2-specific. The target's reputation appears to have been a property of the delivery vehicle. Whether the vehicle also delivers efficacy is the separate and still-unanswered question.

Published Research

14 studies

The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates

ReviewPMID: 42240280

Unlocking the potential of EphA2 with precision-guided cancer therapy: bicycle drug conjugates

A March 2026 review in the Journal of Translational Medicine and the most complete account of why EphA2 defeated earlier agents — MEDI-547, DS-8895a, MM-310 and dasatinib are each discussed by name. Also the source for the construct description as an EphA2-targeting bicyclic peptide linked to MMAE via a valine-citrulline cleavable linker. The important caveat is authorship: all three authors (Bennett, Riedl, Mudd) are Bicycle Therapeutics scientists, and the review's assessment of the compound's differentiated safety profile and promising antitumour activity is a company position, not an independent one.

Review (sponsor-authored)PMID: 41782030

Innovative Peptide Therapeutics in the Pipeline: Transforming Cancer Detection and Treatment

ReviewPMID: 40725089

Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors

The only peer-reviewed clinical dataset for this compound, in the Journal of Clinical Oncology, October 2024. Forty-five patients dosed from 2.2 mg/m2 weekly to 10.0 mg/m2 every two weeks. Establishes the recommended Phase 2 dose of 6.5 mg/m2 every two weeks and reports the figure most often left out of secondary coverage: at that dose the overall response rate was 6.7% and the disease control rate 20.0%. Also the source for the pharmacokinetics that define the platform — a parent half-life of 0.4 to 0.7 hours against an MMAE half-life of 35 to 47 hours — and for the safety profile of nausea 44.4%, diarrhoea 35.6%, fatigue 33.3% and grade 3 or higher neutropenia 22.2%.

Phase 1 Clinical TrialPMID: 39231383

Bioanalysis of the Bicycle toxin conjugate BT5528 and released monomethyl auristatin E via liquid chromatography-tandem mass spectrometry

Bioanalytical MethodPMID: 38088822

Bicyclic Peptide Makes Targeting EphA2 Possible

News / CommentaryPMID: 34666990

MMAE Delivery Using the Bicycle Toxin Conjugate BT5528

The 2020 Molecular Cancer Therapeutics paper that frames the entire programme as an answer to MEDI-547. Describes rapid uptake into tumours and fast renal elimination followed by persistent toxin levels in tumour without prolonged exposure of parent drug in the vasculature, and states that this gave more favourable toxicology findings in rats and monkeys than were observed with MEDI-547 in preclinical and clinical studies. Authored by Bicycle scientists, so the comparison is a sponsor claim — but it is the specific, falsifiable prediction that the clinical safety data have since been consistent with.

PreclinicalPMID: 32398269

NCT04180371 — Phase 1/2 study of BT5528 in advanced malignancies associated with EphA2 expression

Clinical Trial Registry

NCT07450859 — Phase 2 study of nuzefatide pevedotin (BT5528) in metastatic pancreatic ductal adenocarcinoma

The current lead trial, and the record that sets expectations correctly. Phase 2, single-arm monotherapy, 39 estimated participants, objective response rate as the primary endpoint, started 5 March 2026, estimated primary completion March 2029. A 39-patient single-arm study with a response-rate endpoint is a signal-finding design, not a registration path — worth holding in mind against coverage that describes the pancreatic programme as pivotal.

Clinical Trial Registry

NCT07681674 — Bicycle Continued Access Protocol (BiCAP) for participants receiving a Bicycle investigational product

Clinical Trial Registry

Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026 (SEC Form 8-K exhibit, 20 April 2026)

The source for every combination figure on this page, none of which has been peer-reviewed. Fourteen metastatic urothelial cancer patients post-checkpoint-inhibitor, ten with prior enfortumab vedotin, at 6.5 mg/m2 every two weeks with nivolumab 480 mg every four weeks, cutoff 9 February 2026: confirmed response rate 40% (4 of 10) in EphA2-positive tumours and 100% (3 of 3) in EphA2-positive MMAE-naive patients, with responders and patients with at least 16 weeks of stable disease on treatment for a minimum of 56 weeks. One dose-limiting toxicity (grade 3 fatigue, five days), no grade 3 or higher drug-related events of clinical interest, no haemorrhage events. Also states that 8 mg/m2 every two weeks is the preferred monotherapy dose, that more than 150 patients have received the drug, and reports EphA2 expression in all 16 pancreatic xenograft models with 10 of 14 sensitive.

Company Disclosure

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results (SEC Form 8-K exhibit, 17 March 2026)

Company Disclosure

Bicycle Therapeutics plc Annual Report on Form 10-K for the fiscal year ended 31 December 2025

Regulatory Filing

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results (SEC Form 8-K exhibit, 29 October 2026)

Company Disclosure

Quick Facts

Class
Bicyclic Peptide-Drug Conjugate (EphA2 / MMAE)
Tier
C
Evidence
Preliminary
Safety
Limited Data
Updated
Nov 2026
Citations
14PubMed

Also known as

BT5528BT-5528NuzefatideBicycle Toxin Conjugate BT5528

Tags

InvestigationalOncologyBicycle Drug ConjugateEphA2MMAEPancreatic CancerOrphan DrugBicycle Therapeutics

Evidence Score

Overall Confidence42%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.